Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation

Annals of Internal Medicine

Volumn 127, Issue 4, 1997, Pages 285-288

  Martin III, Thomas G ^a   Somberg, Kenneth A ^a   Meng, Y Gloria ^b   Cohen, Robert L ^b   Heid, Christian A ^c   De Sauvage, Frederic J ^b   Shuman, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c Mailstop #37 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; THROMBOPOIETIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RNA ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0030818789     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-4-199708150-00005     Document Type: Article

References (15)

1. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest. 1969;48:963-74.
2. Aster R. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest. 1966;45:645-57.
3. Toghill P, Green S, Ferguson R. Platelet dynamics in chronic liver disease with special reference to the role of the spleen. J Clin Pathol. 1977;30:367-71.
4. Sanyal AJ, Freedman AM, Purdum PP, Shiffman ML, Luketic VA. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology. 1996;23:32-9.
5. Alvarez OA, Lopera GA, Patel V, Encarnacion CE, Palmaz JC, Lee M. Improvement of thrombocytopenia due to hypertension after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol. 1996;91:134-7.
6. McAllister E, Goode S, Cordista AG, Rosemurgy A. Partial portal pressure decompression alleviates thrombocytopenia of portal hypertension. Am Surg. 1995;61:129-31.
7. Ferrara J, Ellison EC, Martin EW Jr, Cooperman M. Correction of hypersplenism following distal splenorenal shunt. Surgery. 1979;86:570-3.
8. Crane C. The choice of shunt procedure for cirrhotic patients with variceal bleeding, ascites and hypersplenism. Surg Gynecol Obstet. 1962;115:12-28.
9. Lok S, Foster DC. The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cells. 1994;12:586-98.
10. de Sauvage FJ, Mass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the C-Mpl ligand. Nature. 1994;369:533-8.
11. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients including cancer patients following chemotherapy with or without peripheral blood progenitor cell transplantation. Br J Haematol. 1996;95:535-41.
12. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94.
13. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74:521-5.
14. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpi ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720-30.
15. Emmons RV, Reid DM, Cohen RL, Meng YG, Young NS, Dunbar CE. et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-71.